Miglustat Accord (Miglustat)

Miglustat is used as a substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids.

• Gaucher disease type 1: reduces substrate buildup, improving hematologic parameters and organ size.
• Niemann‑Pick disease type C: slows neurological decline and stabilises visceral disease.
• Substrate reduction therapy: provides an oral option to lower glycosphingolipid synthesis in approved lysosomal storage conditions.

• Miglustat inhibits glucosylceramide synthase, the enzyme responsible for the first step in glycosphingolipid biosynthesis. By blocking this pathway, the drug reduces the formation of glucosylceramide and downstream glycosphingolipids, decreasing their accumulation in lysosomes and mitigating the pathological substrate load characteristic of certain lysosomal storage diseases.

Miglustat may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Diarrhoea: frequent loose stools, often mild to moderate.
• Nausea: sensation of unease or urge to vomit.
• Abdominal pain: cramping or discomfort in the stomach area.
• Weight loss: unintended reduction in body weight.
• Flatulence: increased intestinal gas.
• Taste alteration: changes in taste perception.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain.
• Severe hypersensitivity: rash, swelling, or anaphylactic reactions.
• Elevated liver enzymes: potential indication of hepatic stress.
• Severe depression or mood changes: may require psychiatric evaluation.
• Seizures: rare neurologic events requiring immediate medical attention.

Before initiating therapy, several safety considerations should be observed.

• Monitor blood glucose: Miglustat can affect carbohydrate metabolism.
• Assess liver function: periodic liver enzyme testing is recommended.
• Evaluate gastrointestinal tolerance: patients should be advised to report persistent diarrhoea or abdominal pain.
• Watch for mood changes: monitor for signs of depression or suicidal ideation.
• Avoid in patients with known hypersensitivity to miglustat or excipients.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Miglustat may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat exposure.
• Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.
• Co‑administration with other substrate reduction agents: risk of additive toxicity.

Moderate Interactions (Monitor Closely)

• Antidiabetic drugs: miglustat can affect glucose control, dose adjustment may be needed.
• Warfarin: potential alteration of INR, requiring closer monitoring.
• Other gastrointestinal irritants: may exacerbate nausea or diarrhoea.